IXICO, the brain health company, today announces that it has signed a new contract worth US$1.2m with a top 15 global pharmaceutical company for advanced imaging clinical trial services in a rare neurodegenerative disease, progressive supranuclear palsy (“PSP”).
The project is for a Phase IIa clinical study of patients in the early stages of PSP to develop a first-in-class therapy that could prevent further degeneration and will utilise IXICO’s TrialTrackerTM and Assessa® digital platforms to collect and analyse MRI data from specialist imaging centres across Europe and North America. The study is expected to complete in 2019 with the potential to be extended further.
This new contract is a further endorsement of the utility of the Assessa® digital platform to quantify disease pathology in regions of the brain measuring disease progression in PSP patients. This is in line with the Company’s strategy to broaden the application of the Assessa® platform to support both the development of novel therapies and the management of patients and treatment decisions in the clinic.